Abeona Therapeutics Inc. Common Stock

ABEONASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
5.46 USD
↘ 0.36 (6.19%)AT CLOSE (11:59 AM EDT)
5.50
↗ 0.04 (0.73%)
POST MARKET (AS OF 05:39 PM EDT)
Post Market
AS OF 05:39 PM EDT
5.50
↗ 0.04 (0.73%)
🔴Market: CLOSED
Open?$5.78
High?$5.83
Low?$5.42
Prev. Close?$5.82
Volume?881.9K
Avg. Volume?1.0M
VWAP?$5.55
Rel. Volume?0.84x
Bid / Ask
Bid?$5.40 × 100
Ask?$5.59 × 1.8K
Spread?$0.19
Midpoint?$5.50
Valuation & Ratios
Market Cap?311.2M
Shares Out?57.0M
Float?48.1M
Float %?88.7%
P/E Ratio?4.71
P/B Ratio?2.15
EPS?$1.16
Dividend?0.00%
Ex-Dividend?N/A

ABEO is currently priced at $5.46. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (45.6%) and a bullish Golden Cross on the moving averages. ABEO is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
226
Market Cap
311.2M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.abeonatherapeutics.com
Listed
1980-09-19
Address
6555 CARNEGIE AVE, 4TH FLOOR
CLEVELAND, OH 44103
Phone: 646-813-4701
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
35
Piotroski F-Score?0/9Weak
Altman Z-Score?-2.42Distress
Confidence?56%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?30.09%Squeeze Risk
Short Interest?14.5M
Days to Cover?10.2
Free Float48.1M
Avg Daily Volume1.4M
Settlement Date2026-05-15
Financial Health
Current Ratio?5.89Strong
Quick Ratio?5.70Strong
Cash Ratio?1.98Strong
Debt/Equity?0.12Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
73/100
P/E?
Peers
100
S&P
97
4.7CHEAP▾
P/B?
Peers
100
S&P
71
2.15CHEAP▾
P/S?
Peers
100
S&P
3
21.40HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.0CHEAP▾
EV/Sales?
Peers
100
S&P
3
18.43HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
90
45.6%STRONG▾
ROA?
Peers
50
S&P
97
33.3%STRONG▾
Cash Flow & Enterprise
FCF?$-85237000
Enterprise Value?$267.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist